Ruminal Microbial Protein Synthesis in Sheep Fed Forages of Varying Nutritive Values

Six wethers, fitted with ruminal and duodenal cannulae, were utilized in a 6 x 6 Latin Square metabolism trial to determine efficiency of microbial protein synthesis in the rumen of sheep fed forages with varying nutritional quality. Ground alfalfa hay, oat-berseem clover hay, and baled corn crop residues were fed at an ad libitum or limited intake level. Chromium-mordanted fiber, cobalt- EDTA, and purines were used to determine digesta flow and solid passage rate, dilution rate, and microbial protein production, respectively. Sheep fed alfalfa hay had greater organic matter (OM) intakes, and amounts of OM apparently and truly ruminally digested (g/d; P < .05) than sheep fed either oat-berseem clover or corn crop residues at the ad libitum intake level. Rates of slow solid and liquid passage, and postfeeding ruminal ammonia-nitrogen (N) and volatile fatty acids (VFA) concentrations were lower (P < .05) in sheep fed corn crop residues than those fed alfalfa or oat-berseem clover hay. Total duodenal flows (g/d) and efficiencies of ruminal synthesis (g crude protein/100 g of OM truly digested; P < .05) of microbial protein were less in sheep fed corn crop residues than in sheep fed alfalfa, and oatberseem clover ad libitum. Whereas total duodenal microbial-N flow was related to organic matter intake (OMI; r2 = .97) and OM truly digested in the rumen (OMTDR; r2 = .97), microbial efficiency was related to g of nitroge truly digested in the rumen (NTDR)/100 g of OMTDR (r2 = .82) and slow solid passage rate (r2 = .91).

Anticoagulation in primary care - a cross sectional study in 14 heterogeneous countries

Background: New oral anticoagulants (NOACs) are predicted to become the new standard treatment for stroke prevention in patients with atrial fibrillation, and may replace vitamin K antagonists (VKAs). NOACs are prescribed less than expected, even though they do not require international normalised ratio (INR) monitoring. In this study we assessed methods for INR monitoring after the introduction of NOACs a in heterogeneous sample of countries. Methods: We asked representatives of the Vasco da Gama Movement, a network of junior and future gen- eral practitioners (GPs) in Europe, and WONCA, the World Organization of Family Doctors, to describe the way INR is monitored in their respective countries. Results: Representatives of 14 countries responded. In most countries, the INR is monitored by GPs; in some countries, these patients are treated by other specialists or in specialised anticoagulation centres. In only a few countries, anticoagulated patients monitor the INR themselves. Conclusion: Our study showed several strategies for managing anticoagulation in different countries. In most countries, the INR is monitored by GPs. These consultations offer opportunities to address other is- sues, such as blood pressure control or medication adherence. These factors may be considered when de- ciding to switch patients from VKAs to NOACs.

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

BACKGROUND: High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compounds (SbV), the treatment of choice for cutaneous leishmaniasis (CL). Paromomycin (PR) has been developed as an alternative to SbV, but existing data are conflicting. METHODOLOGY/PRINCIPAL FINDINGS: We searched PubMed, Scopus, and Cochrane Central Register of Controlled Trials, without language restriction, through August 2007, to identify randomized controlled trials that compared the efficacy or safety between PR and placebo or SbV. Primary outcome was clinical cure, defined as complete healing, disappearance, or reepithelialization of all lesions. Data were extracted independently by two investigators, and pooled using a random-effects model. Fourteen trials including 1,221 patients were included. In placebo-controlled trials, topical PR appeared to have therapeutic activity against the old world and new world CL, with increased local reactions, when used with methylbenzethonium chloride (MBCL) compared to when used alone (risk ratio [RR] for clinical cure, 2.58 versus 1.01: RR for local reactions, 1.60 versus 1.07). In SbV-controlled trials, the efficacy of topical PR was not significantly different from that of intralesional SbV in the old world CL (RR, 0.70; 95% confidence interval, 0.26-1.89), whereas topical PR was inferior to parenteral SbV in treating the new world CL (0.67; 0.54-0.82). No significant difference in efficacy was found between parenteral PR and parenteral SbV in the new world CL (0.88; 0.56-1.38). Systemic side effects were fewer with topical or parenteral PR than parenteral SbV. CONCLUSIONS/SIGNIFICANCE: Topical PR with MBCL could be a therapeutic alternative to SbV in selected cases of the old world CL. Development of new formulations with better efficacy and tolerability remains to be an area of future research.

Purified U7 snRNPs lack the Sm proteins D1 and D2 but contain Lsm10, a new 14 kDa Sm D1-like protein.

U7 snRNPs were isolated from HeLa cells by biochemical fractionation, followed by affinity purification with a biotinylated oligonucleotide complementary to U7 snRNA. Purified U7 snRNPs lack the Sm proteins D1 and D2, but contain additional polypeptides of 14, 50 and 70 kDa. Microsequencing identified the 14 kDa polypeptide as a new Sm-like protein related to Sm D1 and D3. Like U7 snRNA, this protein, named Lsm10, is enriched in Cajal bodies of the cell nucleus. Its incorporation into U7 snRNPs is largely dictated by the special Sm binding site of U7 snRNA. This novel type of Sm complex, composed of both conventional Sm proteins and the Sm-like Lsm10, is most likely to be important for U7 snRNP function and subcellular localization.

Na 1 Nachlass Max Horkheimer, 28 - Korrespondenzen mit u.a. Siegfried Kracauer (p. I 14, 115-368)

95 Briefe und Beilagen zwischen Siegfried Kracauer und Max Horkheimer, 1936-1949; 2 Briefe zwischen Else Staudinger vom American Committee for Refugee Scholars, Writers and Artists New York und Max Horkheimer, 10.07.1945, 24.07.1945; 2 Briefe zwischen Meyer Schapiro und Siegfried Kracauer 19.11.1937, 03.12.1937; 2 Briefe von Leo Löwenthal an Schapiro Meyer, 1940, 1941; 1 Brief und 1 Beilage von Max Horkheimer an A. Schütz, 02.08.1940; 1 Brief von Max Horkheimer an Trude Krautheimer, 30.07.1940; 1 Brief von Max Horkheimer an das Hebrew Sheltering and Immigrant Aid New York, 10.06.1940; 2 Briefe ziwschen dem Department of State Washington und Max Horkheimer, 05.04.1939, 1939; 2 Briefe zwischen Betty Drury Max Horkheimer, 05.11.1938, 07.11.1938; 2 Briefe zwischen Margaret Krafft und Max Horkheimer, 1938, 1939; 1 Brief von Gertrud Kurth-Kieslinger an Max Horkheimer, 02.10.1939; 2 Briefe zwischen Werner Kraft und Max Horkheimer, 19.01.1940, 01.03.1940; 1 Brief und 1 Beilage von Friedrich Krause an Max Horkheimer, 05.01.1939; 2 Briefe zwischen Karl Krayl und Max Horkheimer, 201.10.1937, 25.11.1937; 11 Briefe zwischen Ernst Krenek und Max Horkheimer, 1937-1941; 1 Brief von S. Krezel an Max Horkheimer, 12.02.1936; 1 Brief von Charles I. Krieger an Max Horkheimer, 01.08.1940; 1 Brief von H. Kronstein an Max Horkheimer, 20.05.1935; 3 Briefe zwischen Germaine Krull und Max Horkheimer, 1934, 06.09.1937, 1937; 3 Briefe zwischen Lawrence S. Kubie Sekretär der American Psychoanalytic Association, New York und Max Horkheimer, 11.05.1938, 1938; 5 Briefe und Beilagen zwsichen Julius Kühl und Max Horkheimer, 18.10.1939-1940; 1 Brief von Max Horkheimer an Herr Guggenheim, 20.02.1940; 1 Brief von Julius Kühl an die ESKA, 31.03.1945; 4 Briefe zwischen B. Kugelmann und Max Horkheimer, 1934, 1938, 1939; 1 Brief von Georg Kunzel an Max Horkheimer, 01.08.1930;

Na 1 Nachlass Max Horkheimer, 14 - Korrespondenzen u.a. mit Hugo Fischer und Karl August Wittfogel (p. I 7, 224-429)

1 Brief von Max Horkheimer an Rosel Favez, 03.12.1935; 5 Briefe zwischen Sidney B. Fay von der Bureau of International Search Cambridge, Massachusetts und Max Horkheimer, 1939-1941; 1 Brief von Max Horkheimer an James Feibleman, 02.03.1942; 5 Briefe von Hans Feibelmann an Max Horkheimer, 1936-1937; 2 Briefe zwischen Babette Feigenbaum und Max Horkheimer, 29.04.1941, 05.05.1941; 1 Brief von Arthur Feiler an Max Horkheimer, 15.10.1939; 1 Brief von Max Horkheimer an Adolf Feitler, 03.01.1935; 3 Briefe zwischen Frederick V. Filed von dem American Council Institute of Pacific Relations und Max Horkheimer, 1937, 05.04.1937; 9 Briefe zwischen Thea Field, Lowell Field und Max Horkheimer, 1935-1941; 1 Brief von Max Horkheimer an Finkelstein, 18.09.1941; 7 Briefe zwischen Harry Finkelstein und Max Horkheimer, 1936-1940; 1 Brief von Louis Finkelstein an Robert MacIver, 29.05.1940; 2 Briefe zwischen Louis Finkelstein und Max Horkheimer, 06.06.1940, 04.06.1940; 15 Briefe zwischen Hugo Fischer und Max Horkheimer, 1937-1938; 1 Brief von Hugo Fischer an P. Tillich; 1 Brief von Hugo Fischer an Karl A. Wittfogel, 17.06.1940; 2 Briefe von Max Horkheimer an Ernest Manheim, April 1942; 1 Brief von Alexander Farquharson an Max Horkheimer, 20.01.1940; 3 Briefe zwischen dem Institute of International Education, New York Edgar J. Fisher und Max Horkheimer, Oktober 1938, 18.10.1938; 10 Briefe zwischen Paul Fischer und Max Horkheimer, 1938-1940; 2 Briefe zwischen der Hessian Hills School New York und Max Horkheimer, 21.02.1938, 28.02.1938; 2 Briefe zwischen Dorothy Canfield Fisher und Max Horkheimer, 24.01.1939, 19.01.1939; 1 Brief von Ossip K. Flechtheim an Max Horkheimer, 04.01.1941; 2 Briefe zwischen der University of Minnesota, Minneapolis und Max Horkheimer, 02.08.1945, 15.09.1945; 3 Briefe zwischen Leo Löwenthal und Max Horkheimer, 1943-1945, 17.08.1945; 2 Briefe zwischen der University of Denver, Colorado und Max Horkheimer, 11.05.1943, 28.05.1943; 1 Brief von dem Institute Universitaire De Hautes Etudes Internationales Genf an Max Horkheimer, 25.01.1939; 1 Brief von Hans Kelsen an Max Horkheimer, 30.01.1939; Lebenslauf und 2 Empfehlungsschreiben von Max Fleischmann für Prof. Edwin Borchard; 1 Brief von der Columbia University in the City of New York an Franz Neumann, 17.04.1940; 3 Briefe zwischen Philipp Flesch und Max Horkheimer, 26.03.1940, 1939-1940; 17 Briefe zwischen Babette Fletcher, Theo Fletcher und Max Horkheimer, 1941-1950; 1 Brief von Max Horkheimer an Abraham Flexner, 07.06.1939; 1 Brief von Robert Fließ an Max Horkheimer, 24.10.1938; 1 Brief von der Foreign Policy Association New York an Max Horkheimer, 03.11.1934; 1 Brief von Max Horkheimer an Rudolf Forster, 10.01.1940; 2 Briefe von der Fortune Time & Life Building New York und Max Horkheimer, 1938-1940; 4 Briefe zwischen Siegmund H. Foulkes (Fuchs) und Max Horkheimer, 1936-1937, 31.12.1936; 5 Briefe zwischen Elsie M. Foulstone und Max Horkheimer, 1941; 1 Brief von Mary Fox an Max Horkheimer, 09.12.1938; 5 Briefe zwischen Ernst Fraenkel und Max Horkheimer, 1936-1938; 1 Heiratsanzeige Liesl Frank; 7 Briefe zwischen Philipp Frank und Max Horkheimer, 1937-1939; 6 Briefe zwischen Lothar G. Frank und Max Horkheimer, 1941; 7 Briefe zwischen Felix Frankfurter und Max Horkheimer, 1937-1941; 2 Briefe zwischen Joseph Freeman und Max Horkheimer, 22.11.1944; 1 Brief von der Free Synagogue New York an Max Horkheimer, 14.11.1938; 2 Briefe zwsichen Benjamin Freilichmann und Max Horkheimer, 07.01.1939, 23.01.1939; 2 Briefe zwischen dem Frenkel Travel Service New York und Max Horkheimer, 21.02.1936, 23.02.1936; 2 Briefe zwischen Hugo Freund und Max Horkheimer, 14.11.1938, 18.11.1938; 2 Briefe zwischen Julius A. Jr. Freynick und Max Horkheimer, 11.09.1939, 18.09.1939;

Na 1 Nachlass Max Horkheimer, 673 - Forschungsprojekte über Antisemitismus, Vorurteil, Autorität: Einzeluntersuchungen (p. IX 139 - IX 140.1-14)

Assignements. Anweisungen zu Einzeluntersuchungen des Antisemitismus-Projekts, 1943 und ohne Datum, 15 Blatt; Zum 'Berkeley Projekt on Antisemitism', 1944-1946; Sitzungsprotokolle und Memoranden der 'Los Angeles Branch of the Berkeley Research Project on Social Discrimination', 19.03.1946 - 11.04.1946, Typoskript, 11 Blatt; Frenkel-Brunswik, Else: 1 Brief mit Unterschrift an Max Horkheimer, ohne Ort, 10.01.1944, 6 Blatt; Interview- und Testprotokolle, Typoskript, 33 Blatt; Horkheimer, Max: 1 Brief an Theodor W. Adorno, ohne Ort, 11.10.1945, 5 Blatt; "Traits of the Authoritatian Character", a) Typoskript, 2 Blatt; b) Typoskript, 2 Blatt; c) Typoskript mit eigenhändigen Korrekturen und Ergänzungen, von Max Horkheimer, 2 Blatt; "Hypothese concerning indirect questions of Berkeley Questionaire". Als Typoskript vervielfältigt, 4 Blatt; Frenkel-Brunswik, Else; Sanford, R. Nevitt: "Some Personality Factors in Anti-Semitism", Sonderdruck aus: The Journal of Psychology, 1945, 20, S. 271-291; Levison, Daniel J.; Sanford, R. Nevitt: "A Scale for the Measurement of Anti-Semitism", Sonderdrucke aus: The Journal of Psychology, 1944,17, S.339-370; "'Unconscious' Facism", Excerpt aus: Propaganda Analysis, No. 7, L938, Typoskript 1 Blatt; Löwenthal, Leo: 1 Brief mit Unterschrift an Max Horkheimer, New York, 31.05.1945; Deutsch, Monroe E.: 2 Briefe mit Unterschrift an Max Horkheimer, Berkeley, 1945; 4 Briefe und Beantwortung von Max Horkheimer, Pacific Palisades, 1945; Lundberg, O.: 5 Briefe von Max Horkheimer, Pacific Palisades, 1945-1946; Sanfort, Nevitt: 1 Brief von Samuel H. Flowerman, ohne Ort, 14.06.1947; Statement for Berkeley Public Opinio Study Group Accounts, 19 Blatt;

Na 1 Nachlass Max Horkheimer, 615 - Manuskripte und Typoskripte zu Vorlesungen und Seminaren zu Max Scheler und anderen Philosophen (p. VIII 10b-VIII 14.4)

Vorlesung 1928: "Über Kants Erkenntnistheorie", eigenhändige Notizen, Manuskript, 2 Blatt; "Über das Recht soziologischer Interpretation"; a) Typoskript mit eigenhändigen Korrekturen, 8 Blatt, b) Typoskript mit eigenhändigen Korrekturen, 7 Blatt, c) Manuskript, 5 Blatt; "Notes"; "Max Scheler (1874-1828)", Typoskript mit eigenhändigen Korrekturen, 13 Blatt; "Zitate aus Werken Max Schelers", 6 Blatt; Notizen zur Vorlesung "Politik und Moral" von Max Scheler, 08.05.1928, 4 Blatt; Paul Ludwig Landsberg: "Zum Gedächtnis Max Schelers", Zeitungsausschnitt aus Literarische Rundschau der Rhein-Mainischen Volkszeitung, 25.05.1928, 1 Blatt; "Hegel und das Problem der Metaphysik", Typoskript mit eigenhändigen Korrekturen, 3 Blatt; "Über Schristian Wolff", Vorlesungsmanuskript, 6 Blatt; Friedrich Pollock: "Über antike und christliche Geschixhtsauffassung", eigenhändige Notizen, 4 Blatt; Diskussion zwischen Max Horkheimer, Mannheim, Tillich und Adorno, u.a. über Wissensoziologie und Pragmatismus, 16.01.1931, Mitschrift von Leo Löwenthal, Typoskript, 2 Blatt; Diskussion zwischen Max Horkheimer, Mannheim, Tillich und Adorno, u.a. über das Verhältnis von Philosophie und Wissenschaft gegenüber dem Schrecken. Mitschrift von Friedrich Pollock, 19.06.1931; a) Typoskript, 3 Blatt, b) eigenhändige Notizen, 12 Blatt; "Thesen über Wissenschaft. Bearbeitung Löwenthal", Frühjahr 1932, Typoskript, 5 Blatt; Friedrich Pollock: Notizheft, eigenhändige Notizen, 1 Heft, 19 Blatt und 8 zusätliche Blätter (enthält u.a.: "Zur heutigen Lage des Idealismus", Notizen zum Vortrag "Der Gegensatz von 'Geist' und 'Leben' in der gegenwärtigen Naturphilosophie" von Ernst Cassirer, gehalten am 03.10.1928; "Zur Kritik der gegenwärtigen Philosophie"; Disposition der Vorlesung von Max Horkheimers "Materialismus und Idealismus in der Geschichte der neueren Philosophie", Wintersemester 1928/29, 23.09.1928 und "Heidegger"); "Materialismus und Idealismus in der Geschichte der neuen Philosophie", Vorlesung Wintersemester 1928/29, (enthält: Vorlesungsmanuskript, 1 Heft, 8 Blatt und 22 zusätzliche Blätter; Friedrich Pollock: Kollegheft zur Vorlesung, 1 Heft, 48 Blatt, davon 9 leer, beiliegend eigenhändige Notizen zu einem Vortrag von Prinzhorn (?) über Lebensphilosophie und Psychoanalyse, 22.12.1928, 10 Blatt; Friedrich Pollock: Kollegheft zur Vorlesung, 05.-15.02.1929, 1 Heft, 12 Blatt, davon 4 leer, und 2 zusätzliche Blätter; Friedrich Pollock, Kolegheft zur Vorlesung, 22.-26.02.1929, 1 Heft, 7 Blatt);

14-3-3zeta overexpression in multiple human cancers plays a critical role in cancer progression

14-3-3 is a family of highly conserved and ubiquitously expressed proteins in eukaryotic organisms. 14-3-3 isoforms bind in a phospho-serine/threonine-dependent manner to a host of proteins involved in essential cellular processes including cell cycle, signal transduction and apoptosis. We fortuitously discovered 14-3-3 zeta overexpression in many human primary cancers, such as breast, lung, and sarcoma, and in a majority of cancer cell lines. To determine 14-3-3 zeta involvement in breast cancer progression, we used immunohistochemical analysis to examine 14-3-3 zeta expression in human primary invasive breast carcinomas. High 14-3-3 zeta expression was significantly correlated with poor prognosis of breast cancer patients. Increased expression of 14-3-3 zeta was also significantly correlated with elevated PKB/Akt activation in patient samples. Thus, 14-3-3 zeta is a marker of poor prognosis in breast cancers. Furthermore, up-regulation of 14-3-3 zeta enhanced malignant transformation of cancer cells in vitro. ^ To determine the biological significance of 14-3-3 zeta in human cancers, small interfering RNAs (siRNA) were used to specifically block 14-3-3 zeta expression in cancer cells. 14-3-3 zeta siRNA inhibited cellular proliferation by inducing a G1 arrest associated with up-regulation of p27 KIP1 and p21CIP1 cyclin dependent kinase inhibitors. Reduced 14-3-3 zeta inhibited PKB/Akt activation while stimulating the p38 signaling pathway. Silencing 14-3-3 zeta expression also increased stress-induced apoptosis by caspase activation. Notably, 14-3-3 zeta siRNA inhibited transformation related properties of breast cancer cells in vitro and inhibited tumor progression of breast cancer cells in vivo. 14-3-3 zeta may be a key regulatory factor controlling multiple signaling pathways leading to tumor progression. ^ The data indicate 14-3-3 zeta is a major regulator of cell growth and apoptosis and may play a critical role in the development of multiple cancer types. Hence, blocking 14-3-3 zeta may be a promising therapeutic approach for numerous cancers. ^